Santen Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Santen Pharmaceutical has a total shareholder equity of ¥288.3B and total debt of ¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ¥409.1B and ¥120.8B respectively. Santen Pharmaceutical's EBIT is ¥51.0B making its interest coverage ratio 333.1. It has cash and short-term investments of ¥84.4B.
Key information
0%
Debt to equity ratio
JP¥0
Debt
| Interest coverage ratio | 333.1x |
| Cash | JP¥84.44b |
| Equity | JP¥288.25b |
| Total liabilities | JP¥120.83b |
| Total assets | JP¥409.09b |
Recent financial health updates
No updates
Recent updates
Santen Pharmaceutical (TSE:4536) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Nov 18
Santen Pharmaceutical Co., Ltd. Just Beat EPS By 5.5%: Here's What Analysts Think Will Happen Next
Nov 11Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Share Price Could Signal Some Risk
Oct 14Calculating The Intrinsic Value Of Santen Pharmaceutical Co., Ltd. (TSE:4536)
Aug 31Santen Pharmaceutical Co., Ltd. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 08Unpleasant Surprises Could Be In Store For Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Shares
Jun 25Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
May 11Is There An Opportunity With Santen Pharmaceutical Co., Ltd.'s (TSE:4536) 34% Undervaluation?
May 08Financial Position Analysis
Short Term Liabilities: 4536's short term assets (¥218.5B) exceed its short term liabilities (¥83.9B).
Long Term Liabilities: 4536's short term assets (¥218.5B) exceed its long term liabilities (¥37.0B).
Debt to Equity History and Analysis
Debt Level: 4536 is debt free.
Reducing Debt: 4536 had no debt 5 years ago.
Debt Coverage: 4536 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 4536 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/18 12:20 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Santen Pharmaceutical Co., Ltd. is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Philip Hall | BNP Paribas Securities (Asia) |
| Koichi Mamegano | BofA Global Research |